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Abstract
Gene expression is tightly regulated via a myriad of mechanisms in the cell to allow canoni-
cal processes to occur. However, in the context of cancer, some of these mechanisms are 
dysregulated, and aberrant gene expression ensues. Some of the dysregulated mechanisms 
include changes to transcription factor activity, epigenetic marks (such as DNA methyla-
tion, histone modifications and chromatin state), or the stability of mRNA and protein. 
Disruption of these regulators would result changes in transcriptional landscape, affecting 
multiple pathways and eventually lead to continual cell proliferation and the formation of 
the tumor. Here, we discuss epigenetic factors that affect gene expression which are dys-
regulated in cancer, and summarize the therapeutic options available to target these factors.
Keywords: cancer, gene regulation, epigenetics, chromatin remodelers, histone 
modifications, DNA methylation, transcriptional regulation
1. Introduction
Genetic information in cells is stored as DNA, and are the same in all cells of a single organ-
ism. The method in which the same code can lead to the translation of multiple different pro-
teins in a tissue-specific manner lies in the regulation of expression of specific genes encoded 
by DNA. Gene expression involves the transcription of DNA to RNA, and in some cases, 
translation into proteins. The gene products which consist of translated and non-coding 
RNAs (RNAs of which the RNA is its final product and does not get translated to protein) 
have different but very important functions in the cell. Collectively, the combination of the 
genes which are expressed and those which are silenced are crucial in maintaining normal 
processes in the cell, determining when it should proliferate or divide etc.
To ensure that gene expression is kept in check, its regulation is multi-tiered and can be 
altered/halted at every step of the gene expression process. This ensures that even if one of 
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these regulatory events goes awry, there are other mechanisms in the cell in place to curb 
aberrant gene expression. Numerous alterations in the multi-tiered process often lead to aber-
rant gene expression and abnormal function in the cell, which occurs in the case of cancer.
Cancer is the result of a cell escaping from its natural cell cycle, evading apoptosis which leads to 
uncontrolled and abnormal proliferation. The transformation of a normal cell into a malignant 
one results from the increase in expression of oncogenes, with a concomitant decrease in tumor 
suppressor expression. Oncogenes are involved in functions which lead to uncontrolled prolif-
eration and growth, evading the canonical apoptotic mechanisms, while tumor suppressors 
curb these mechanisms. Although cancer cells of different tissue types have the same outcome 
of uncontrolled growth, the mechanisms involved are varied. Even within the same tissue, 
malignancies are very heterogeneous, contributing to the challenge in treating this disease.
In this chapter, we will summarize the multiple layers of gene regulation, focusing on the dys-
regulated epigenetic changes in cancer involved in gene expression regulation. We then sum-
marize the therapeutic options available which seek to curb these gene regulation changes.
2. Transcriptional regulation
Gene expression is regulated by many varying factors governing different stages of this complex 
process. The regulatory process begins from the chromatin conformation defining its state, either 
euchromatin/open chromatin, allowing active transcription, or a repressive heterochromatin/
closed chromatin, illustrated in Figure 1A. The open chromatin is actioned by several factors, 
including acetylated histone tails and the inclusion of specific histone variants which act to desta-
bilize the nucleosome. This is often tested by DNase hypersensitivity assays, which measure the 
sensitivity of DNA to enzymatic digestion. Portions of the DNA with nucleosomes loaded would 
be protected from DNase digestion, while nucleosome depleted regions (NDR) are sensitive.
The idea of topological domains was suggested recently by Dixon et al. [1], which describe a 
section of the genome of which its enclosed genes are generally co-regulated. The boundaries 
of these topological domains interact in 3D space and are marked by the presence of CCCTC-
binding factor (CTCF) and cohesin. There have been mutations observed in these topologi-
cally associated domains (TADs), which will be described later in this chapter.
On the DNA level, the region of the genome around the transcription start site (TSS) is particu-
larly important in the regulation of gene expression as that is where transcription machinery 
and co-regulators bind. Proteins known as transcription factors are able to recognize motifs/
transcription factor binding sites on the promoters of genes, and recruit RNA Pol II and/or 
phosphorylate Pol II to initiate transcription. Alternatively, transcription regulators can also 
inhibit the binding or recruitment of the transcription complex. In addition to the TSS, recent 
studies have also identified that distal regulatory elements, such as enhancers, are able to regu-
late expression as well. Both enhancers and promoters can be marked by different histone mod-
ifications which can be read and have an impact on the expression of its corresponding gene.
Regulatory processes that affect the stability of mRNA and proteins are equally as important 
as gene expression factors but will not be addressed in this chapter. These include microRNA 
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(miRNA) which have the ability to degrade mRNA and thus prevent it from being translated 
to proteins, and also endogenous systems which degrade proteins.
Studies have shown that every step of the gene expression regulation can be exploited by 
cancer cells to prolong survival and contribute to tumorigenesis. Considering the vast nature 
of this topic, we will be focusing on the multiple epigenetic factors regulating gene expression 
which are dysregulated in cancer. However, dysregulated transcription factors form a huge 
Figure 1. Illustration of selected methods of gene regulation. (A) Repressive heterochromatin state wherein transcription 
machinery is not able to bind to DNA, compared to activating, euchromatic state permissive of transcription activation. 
(B) CpG islands upstream of TSS are often hypermethylated in cancer, repressing transcription, while CpG islands 
in the rest of the genome are hypomethylated. These methylated CpG marks are read by protiens containing methyl 
CpG-binding domains (MBD). These methylation states are reversed in cancer, allowing transcriptional activation. (C) 
Histone tails are able to undergo multiple covalent modifications such as acetylation, methylation, phosphorylation and 
ubiquitination. In cancer, histone tails are often observed to be hypoacetylated and therefore repressing transcription. 
(D) Mediator and cohesin enabling long-range chromatin interactions to occur, therefore bringing together the proximal 
(promoter/TSS) and distal (enhancer) regulatory regions. During the process of tumor growth, non-canonical enhancer 
usage often occurs, resulting in aberrant gene expression.
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topic of interest in cancer research. This includes work on tumor suppressor p53 (reviewed in 
[2–4]) and the oncogene MYC (reviewed in [5, 6]), amongst others.
3. Epigenetic regulators of gene expression
Epigenetics is an additional layer of complexity to the genetic code, and comprise of addi-
tional information (in the form of compounds added or secondary structures) on top of the 
four basic nucleotides: adenine, thymine, cytosine and guanine. This allows a gene with the 
same genetic sequence to be differentially regulated according to cell type or context. This 
occurs through mechanisms such as binding of transcription factors and machinery. These 
epigenetic changes and modifications allow for greater control and regulation for gene 
expression by transcription factors. Here, we will discuss the myriad of epigenetic features 
that can contribute to gene expression.
3.1. Chromatin modifications
It is only through the compaction of DNA in a nucleosome that the long length of DNA is 
packaged into the nucleus of each cell. A length of 146 bp of DNA is coiled around a histone 
octamer, consisting of two residues each of H2A, H2B, H3 and H4, secured in place by H1. It is 
linked to its neighboring nucleosome via linker DNA, varying between 20 and 80 nucleotides 
in length. The placement and composition of nucleosomes are not at all random. Rather, its 
content and position is strategically coordinated to regulate gene expression on several dif-
ferent layers.
Although the terms are used interchangeably in literature, in this chapter, we will address 
chromatin modifiers and remodelers as two separate groups of enzymes, the former covalently 
modifying histone, and the latter regulating the position and composition of the nucleosomes.
3.1.1. Chromatin modifiers
Chromatin modifiers consist of a group of enzymes that post-translationally modify histones, 
resulting in histone modifications that make up the histone code. Covalent modifications on 
these histones can consist of acetyl, methyl, ubiquitin, phosphoryl groups, amongst others. 
The specific modifications which are added to different histones determines its function and 
its role in the cell, as represented in Figure 1C. A summary of these modifications and its 
related downstream effect was investigated by the ENCODE team, and summarized in their 
paper in 2012 [7].
Histone modifications can occur on different regulatory regions of a gene, such as at its pro-
moter, enhancer or even along the gene body. The presence of an active mark on the promoter, 
for an example, recruits other transcriptional machinery factors, and allows transcription to 
occur. These histone modifications are not permanent, and can differ between tissue types or 
depending on its cellular state. The regulation of histone modifications is a balance between its 
epigenetic writers and epigenetic erasers, and the dysregulation of either would result in aberrant 
histone modifications and thus a change in the transcription. The group of proteins that are 
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involved in interpreting these histone marks, epigenetic readers, are also crucial, whose dys-
regulation could result in the misinterpretation of the epigenetic marks and therefore a change 
in transcriptional landscape.
A point to note is only a subset of these residues can undergo multiple modifications. For exam-
ple, lysine 27 on histone 3, can be either acetylated (in active enhancers) or tri-methylated (a 
mark of repressed promoters), each of which contributes to a different transcriptional outcome. 
It is also hypothesized that the addition of a particular covalent modification sterically inhibits 
the alternate modification. Additionally, histone marks on the enhancers such as H3K4me and 
H3K27ac are capable of regulating the 3D structure of chromatin. Since this method of regula-
tion is indeed another layer that the cell regulates gene expression in a normal setting, it comes 
as no surprise that chromatin modifiers are known to be dysregulated in cancer, resulting in the 
aberrant expression of its downstream genes (lysine acetyltransferases (KATs) reviewed in [8], 
histone methyltransferases (HMTs) reviewed in [9], histone deacetylases (HDACs) reviewed in 
[10–12], histone demethylases reviewed in [13, 14]). Here, we will focus on epigenetic factors 
which are dysregulated in cancer, resulting in a transcriptional change.
3.1.1.1. Epigenetic writers
Epigenetic writers are enzymes that have the ability to deposit the moiety onto histone tails, 
and have to work in balance with epigenetic erasers to ensure the presence of the correct 
histone modification to govern the required transcriptional program. All epigenetic writ-
ers require a catalytic domain which allows the enzymatic reaction of the moiety transfer to 
occur, and another domain which allows the recognition of the chromatin.
Another class of chromatin modifiers are KATs which are involved in acetylating lysine resi-
dues on histones. This is perhaps the most crucial modification on histone tails as it not only 
marks histones to be read by epigenetic readers, but the acetylated histones also allow the 
relaxation of chromatin conformation. Acetyl groups neutralize the positive charge of his-
tones, therefore loosening the conformation of nucleosomes in turn allowing the binding of 
transcription initiation complex to chromatin, resulting in gene activation. The decrease in 
acetylated histones is a phenomenon observed in multiple cancers as depicted in Figure 1C, 
along with its permissive state, as seen with global levels of H4K16ac decreased in lympho-
mas when compared to normal [15].
TIP60 (HIV-Tat1 interactive protein 60 kDa) is an acetyltransferase, a member of the MYST (Moz, 
Ybf2p/Sas3p, Sas2p and TIP60) family, known to acetylate both histones and non-histone pro-
teins. Although it has been shown to have a bivalent role in the process of carcinogenesis (depen-
dent on cancer type), strong evidence has supported its role as a tumor suppressor [16, 17]. 
TIP60 exerts its tumor suppressive phenotype through acetylating several substrates in the cell, 
one of which is ataxia-telangiectasia mutated (ATM) at DNA damage sites [18, 19]. Additionally, 
TIP60 is also known to acetylate p53 at lysine 120, crucial in mediating the switch between cell-
cycle arrest or apoptosis [20]. It was also recently shown that TIP60 is able to repress telomerase 
transcription by acetylating Sp1, therefore inhibiting its binding on TERT promoter [21].
In support of its role as a tumor suppressor, the levels of TIP60 was found to be lower in tumor 
compared to its matched normal in multiple cancers including breast [16] and colon [22]. 
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The downregulation of TIP60 occurs through several mechanisms, including regulation at 
mRNA level by miR-22 [23] or via proteosomal degradation by the human papillomavirus 
(HPV) oncogene E6 through EDD1, an E3 ubiquitin ligase [17]. TIP60 has been shown to 
regulate transcription at the integrated HPV promoter via the acetylation of H4, and therefore 
repress the expression of E6 [24, 25].
GCN5 (general control of amino acid synthesis protein 5-like 2) is another acetyltransferase 
which acetylates H3K9, H3K14, marks of active transcription [26], and when part of the SAGA 
(Spt-Ada-GCN5-Aceyl transferase) complex, acetylates H3 and H2B. Its link with cancer is 
primarily through the oncogene MYC, which recruits the SAGA complex to chromatin, where 
GCN5 functions to activate its gene targets [27]. Since MYC is a substrate of GCN5 and when 
acetylated at K323 increases its stability, both proteins are maintained in a positive feedback 
loop [28]. GCN5 is also crucial in ALL (acute lymphoblastic leukemia) via the acetylation and 
stabilization of the oncogenic fusion protein E2A-PBX1 [29], leading to aberrant expression of 
HOX genes, therefore leukemogenesis [30].
The dysregulation of methyltransferases have also been implicated in the severity and pro-
gression of cancer. In particular, G9a is responsible for the mono and di-methylation of H3K9, 
which are characteristic of a transcriptionally repressed gene. G9a has been found to be 
involved in epigenetically silencing numerous tumor suppressor genes, such as DSC3 (des-
mocollin 3) and CDH1 (cadherin 1), with the repression of G9a resulting in rescue of tumor 
suppressive gene expression [31]. Recent studies have shown the upregulation of G9a in 
tumors, leading to the aberrant methylation of H3K9 and thus silencing of tumor suppressor 
and growth inhibitory factors [32, 33]. In both lung and breast cancers, G9a exerts these effects 
through regulating epithelial-mesenchymal transition (EMT) factors such as EpCAM (epi-
thelial cell adhesion molecule) and Snai1 (snail family transcriptional repressor 1) [34, 35]. In 
AML (acute myeloid leukemia), the depletion of G9a results in late disease onset and a reduc-
tion of leukemia stem cell frequency, although there was no observable function in hemato-
poietic stem cells [36]. This was identified to occur through the regulation of transcription in 
a HOXA9-dependent manner. In addition, G9a also has alternate roles in the cell, acting as 
both a transcriptional co-repressor and co-activator. As a transcriptional co-repressor, G9a has 
been found to be present in the same protein complex as JARID1A, the H3K4 demethylase, 
while it acts as transcriptional co-activator through stabilization of the mediator complex [37].
EZH2 is the enzymatic subunit of the polycomb repressive complex 2 (PRC2) which methyl-
ates lysine 27 of histone H3, resulting in chromatin compaction and transcriptional silencing 
[38, 39]. EZH2 overexpression has been observed in a myriad of different cancers includ-
ing prostate, breast, bladder and endometrial (reviewed in [40]). Several independent studies 
have shown that this gain-of-function mutation on EZH2 is able to contribute to cell prolifera-
tion [41] and neoplastic transformation in breast epithelial cells [42], which is dependent on 
EZH2’s methyltransferase domain. In addition, mutations have been found in the H3K27me3 
demethylase, UTX [43], further contributing to dysregulated tri-methylation of H3K27.
3.1.1.2. Epigenetic readers
The faithful expression and activity of epigenetic readers are also crucial in regulating his-
tone modifications, the dysregulation of which would lead to histones being modified for an 
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extended amount of time, resulting in a cascade of downstream effects. A group of epigenetic 
readers are the ING (inhibitor of growth) family which contains PHD (plant homeodomain) 
finger at its C terminus, with the ability to read methylated lysine 4 of histone 3 [44, 45]. ING 
readers are present in numerous protein complexes, which allow the interpretation of the 
histone tails to be actioned. ING1 and ING2 are able to recruit mSin3-HDAC transcriptional 
repressors while ING3, ING4 and ING5 interact with HATs to activate a downstream gene 
expression [46, 47]. ING family members have been implicated in many cellular processes with 
tumorigenic features such as cell cycle progression, apoptosis, DNA repair and senescence 
[48]. Because of its prominent role in the development of tumors, cancer cells have exploited 
this mechanism, with loss-of-function mutations in INGs observed in many solid tumors [48].
Although acetylated histones can exert transcriptional change by itself through the regula-
tion of chromosomal conformation, the acetylated marks can be read by epigenetic readers 
and result in further gene expression changes. Extensive studies have been carried investigat-
ing the readers of acetylation marks—bromodomain-containing proteins. Bromodomain and 
extra-terminal (BET) proteins are a subset of this family, consisting of BRD2, BRD3, BRD4 and 
BRDT. BRD4 has shown to recruit the elongation factor P-TEFβ [49, 50], thus facilitating the 
transcription by RNA Pol II, resulting in gene activation. In other cases, BRD4 is also known 
to recruit repressive machinery [24].
3.1.1.3. Epigenetic erasers
Epigenetic erasers are capable of removing the histone modifications applied by the epigen-
etic writers, and are crucial in ensuring that histone modifications are removed in a timely 
manner to prevent aberrant transcription from occurring.
The larger of the two classes of histone demethylases are the family of proteins that contain 
the Jumonji C (JmJC) domain, of which JARID1B (also known as KDM5A) is a member. It 
has been identified to remove the methylation marks from lysine 3 of histone 4. Its down-
stream targets comprise of tumor suppressor genes, including BRCA1 and Caveolin 1, whose 
promoters JARID1B demethylates and therefore suppresses its expression [51, 52]. Not sur-
prisingly, JARID1B was found to be overexpressed in late stage breast and prostate cancer 
[51, 53]. Similarly, KDM4A and KDM4B have been identified as proto-oncogenes, interact-
ing with ERα to regulate pro-tumorigenic factors such as MYC [54]. KDM4A, in particular, 
blocks cellular senescence through transcriptionally repressing the tumor suppressor CHD5 
[55]. Interestingly, KMD4C was discovered to increase the amount of euchromatin in the cell 
through delocalizing HP1 (a repressive protein), therefore allowing transcription [56].
HDACs are able to remove the acetyl groups from histone tails, and are divided into four 
classes based on their similarity with their yeast homologs. The most well-studied class of 
HDACs is the class I subfamily (consisting of HDAC1, HDAC2, HDAC3 and HDAC8), where 
all the members have been linked to cancer. The upregulation of HDAC1 has been associ-
ated with poor prognosis in several solid tumors such as lung, prostate and liver [57, 58], 
and even as an independent prognostic marker in breast tissues [59]. Along similar lines, the 
transient depletion of HDAC1 and HDAC3 the cervical cancer cell line, HeLa, resulted in 
decreased cell proliferation [60]. Links between the class II HDAC genes and lung cancer has 
also been drawn, when HDAC genes from 72 NSCLC (non-small cell lung cancer) patients 
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were  measured via real-time PCR [61]. It was found that lower expression of class II HDAC 
genes was correlated with poorer prognosis, of which HDAC10 was the strongest predictor 
of patient outcome.
3.1.2. Chromatin remodelers
Chromatin remodelers are enzymes that are able to make structural changes to the nucleo-
some, either by adding or ejecting a nucleosome, or by moving the nucleosome along the string 
of DNA (reviewed in [62]). This acts as one of the first steps of gene expression regulation, 
allowing the DNA to be exposed to other biological factors to be read and therefore expressed.
There are four chromatin remodeler families that utilize ATP hydrolysis to facilitate the catal-
ysis of these movements along the string of DNA, NuRD/Mi-2/CHD, switch/sucrose non-
fermenting (SWI-SNF), inositol requiring 80 (INO80) and imitation switch (ISWI). There is at 
least one epigenetic reader protein in each of the complexes, which allow the recognition of 
the nucleosome prior to its ejection or relocation.
Similar to other dysregulated factors in cancer, chromatin remodelers have an important 
responsibility in regular gene expression, and therefore have been exploited in cancer cells 
as a mechanism which leads to uncontrolled proliferation. Although there has been extensive 
research into mutations of members of chromatin remodeling families, limited evidence has 
linked these mutations to epigenetic alterations and changes in the chromatin architecture.
In the SWI/SNF complex, BRG1 and SNF5 are required for maintaining nucleosome position-
ing at the −1 and +1 positions around the TSS of repressed genes. Up to 20% of human tumors 
are known to contain at least one mutation in SWI/SNF [63], although BRG1 was found to 
have dual effects in both the promotion and suppression of tumorigenesis [64–67]. In spite of 
many studies carried out to characterize the mutations of SWI/SNF components, there are far 
fewer studies that identified the epigenetic implications of these mutations (reviewed in [68]). 
It was found that in the absence of either BRG1 or SNF5, there was a decrease in the distance 
between nucleosomes on both sides of the TSS, indicating that chromatin condensation is 
augmented upon SWI/SNF dysregulation [69]. SWI/SNF is also known to interact with other 
chromatin modifiers, whose interaction is altered when there is a change observed in SWI/
SNF. As an example, SWI/SNF complex antagonizes PRC2’s repressive activity by removing 
it from gene promoters, resulting in open chromatin conformation and therefore increase in 
gene expression [70, 71].
3.1.3. Histone variants
Histone variants are non-canonical versions of three histone subunits (all but H4), some with 
as few as one amino acid difference between its wildtype counterpart. Histone variants being 
highly conserved across different species eludes to its important cellular function separate 
from that of the canonical histones [72, 73].
The placement of histone variants in nucleosomes in specific portions of the genome have dif-
ferent abilities to regulate nucleosomal stability, dynamics and structure, and therefore tran-
scriptional machinery. For example, the presence of H2A.Bbd results in loosened  chromatin 
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and therefore encouraging transcription [74]. As with canonical histones, histone variants 
are also subject to covalent modifications (acetylation, methylation etc.) and mutations, and 
therefore add an additional layer of complexity to understanding its function and role.
Many of these histone variants have been found to have a role in cancer (reviewed in [75]), 
some with oncogenic and others with tumor suppressive abilities, differing based on its role 
in the cell. Some of the strongest correlations between histone variants and regulating tran-
scription occurs at a macro level, in which histone variants regulates the stability of its nucleo-
some. Nucleosomes that contain H2A.Z or H3.3 were shown to be less stable, although they 
are known to occupy the normally nucleosome-depleted regulatory regions [76]. Their pres-
ence on these regulatory sites inhibit the formation of stable repressive nucleosomes, and due 
to its labile nature, can be displaced easily by transcription regulators, therefore facilitating 
gene expression [77].
In addition to histone variants affecting the overall nucleosome structure, in some instances, 
the readers of histone variants are different from that of canonical histones. The reader of 
H3.3K36me3 was identified to be the tumor suppressor protein ZMYND11 (zinc finger 
MYND-type containing 11), which regulates RNA Pol II, hence linking histone variants and 
transcriptional elongation [78]. Further, an increase in acetylation of H2A.Z was observed in 
prostate cancer, particularly around the promoters of actively transcribed genes, thus result-
ing in the aberrant activation of genes [79].
3.1.4. Chromatin conformation
Regions of the DNA which are known to interact frequently are classified as TADs, which can 
range up to several million nucleotides in length, and several factors are thought to be associ-
ated with the boundaries of these domains, including CTCF and cohesin [1]. Characteristic 
features of TADs include the lower frequency of interaction of gene domains between TADs 
while genes within the same TADs are often co-regulated, sharing the same genetic profile 
(reviewed in [80]).
Given the role of TADs in regulating gene expression, it should come as no surprise that 
this cellular process is also exploited in cancer cells. Disrupted TAD boundaries have been 
found present in cancer cells, allowing ‘enhancer hijacking’ to occur, where enhancers do not 
act on their canonical targets alone, resulting in aberrant expression of non-canonical genes, 
illustrated in Figure 1D. It was found that GFI1 and GFI1B, members of the growth factor 
independent 1 family of proto-oncogenes, were upregulated not by amplification in medul-
loblastoma, but instead activated by enhancer hijacking, coming under the control of an aber-
rant active enhancer [81].
Similarly, viral oncogenes encoded by Epstein–Barr virus (EBV) was found to hijack DNA 
looping, leading to the association of two key genes, MYC and BCL2L11 (a pro-apoptotic 
factor) to non-canonical enhancers [82]. Through the transactivator EBNA2, the MYC locus 
was reconfigured to be regulated by a non-canonical enhancer, resulting in the activation 
of the oncogene, promoting tumor formation. Concurrently, EBV repressors EBNA3A and 
EBNA3C were shown to be capable of recruiting EZH2, thus silencing the upstream regula-
tory enhancer hub.




The mediator complex is a large, 26 subunit complex which coordinates the many different 
elements required for the activation of gene transcription. This includes the cross-talk between 
RNA Pol II and transcription factors that possess sequence-specific recognition sites, and also 
distal regulatory regions such as enhancers. The CDK8 module, consisting of MED12, CDK8, 
Cyclin C and MED13 [83], has been identified as a key component of the complex, function-
ing as a molecular switch [84] and therefore regulating the activity of the mediator complex. 
Due to its crucial role in regulating transcription, cancer cells have exploited this mechanism 
to lead to aberrant gene expression.
MED12 is a member of the complex, of which frequent mutations at the N-terminus have 
been found in prostate cancer, uterine leiomyosarcomas [85], breast adenomas [86] and phyl-
lodes [87]. Specifically, the mutations in MED12 disrupts the interaction between MED12 and 
CDK8, therefore rendering the CDK8 module inactive, therefore decreasing the activity of the 
mediator complex [88–90].
3.2. DNA methylation
One form of epigenetic regulation is CpG (5′ cytosine phosphate guanine 3′) methylation, which 
refer to the addition of methyl groups to the carbon residue at the fifth position on cytosine, 
exclusively where cytosine directly precedes guanine. These methyl moieties are modified and 
interpreted by three distinct groups of proteins, DNA methylation writers, readers and editors.
DNA methylation writers consist of proteins from the DNA methyltransferase (DNMT) fam-
ily, namely DNMT1, DNMT3A, DNMT3B [91, 92]. De novo methylation patterns are added by 
DNMT3A and DNMT3B in response to stimuli in different contexts, while DNMT1’s primary 
role is in the maintenance of the methyl groups, allowing it to be inherited across cell divi-
sions. The effects of CpG methylation is mediated by the reader proteins from three separate 
families of proteins- methyl-CpG-binding domain (MBD) proteins, the SET- and Ring finger-
associated (SRA) domain family and the Kaiso family of proteins [93–96]. These proteins are 
endowed with the ability to bind to CpG methylation and recruit other factors to exert regula-
tory roles in the cell [97, 98]. Finally, DNA methylation editors are able to oxidize the existing 
methyl group on carbon-5, and convert it to form a 5-hydroxylmethylcytosine (5-hmC), which 
undergo further chemical modifications before resuming its unmethylated state [99].
Not surprisingly, there have been reports linking all three groups of the above-mentioned pro-
teins with cancer, leading to a global hypomethylation of repetitive elements and CpG-poor 
regions but a hypermethylation at CpG islands [100]. Approximately 15% of CpG sites are situ-
ated directly upstream of genes within CpG islands, with the remainder of the genome having 
relatively sparse CpG sites (reviewed in [101]). CpG islands are regions in the genome span-
ning between 300 to 3000 nucleotides which contain a high density of CpG dinucleotides, and 
are present at about 60% of human promoters [102], while CpG island shores are regions 2 kb 
flanking the CpG islands [103]. CpG islands have been shown to be sites of transcription initia-
tion, evidenced by several features; TSS have been found within CpG islands, RNA Pol II found 
to co-localize to the islands, and the active histone mark H3K4me3 was found to be within the 
islands [104, 105]. CpG islands are thought to regulate gene expression in two distinct manners. 
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First, it has been shown that the methylated CpG dinucleotide is capable of sterically hinder-
ing the binding of transcription factors and co-activators [106]. Cancer cells have exploited 
this mechanism to silence tumor suppressor genes, with a global hypermethylation of CpG 
islands observed across multiple cancer types, depicted in Figure 1B [101, 107–109]. Secondly, 
the MeCP1 proteins, a class of DNA methylation readers, have been shown to recruit HDACs, 
responsible for deacetylating histones, therefore condensing the chromatin, ultimately leading 
to a decrease in transcription [107].
MBD proteins have been implicated in multiple cancers (reviewed in [110]), with its muta-
tion and overexpression resulting in uncontrolled cell proliferation. In prostate cancer, it was 
discovered that MBD2 overexpression is associated in the aberrant hypermethylation and 
therefore suppression of GSTP1 tumor suppressor, as is with TERT in HPV-positive cells 
[111–113]. Recently, there was an unexpected finding that MBD2 was associated with DNMT1 
and DNMT3A, and the loss of MBD2 resulting in global hypomethylation, eventuating in 
both downstream gene activation and repression [114]. In particular, the hypomethylation 
observed at CpG islands and shores were the same regions that were hypermethylated in pros-
tate cancer patients, eluding to the critical role of MBD2 in rewriting the cancer methylome.
The TET (ten-eleven translocation) family of proteins has also been implicated in several dif-
ferent types of cancer, with most studies carried out in hematological malignancies. It was in 
blood that TET1 was first implicated in cancers, identified as a fusion partner in mixed lineage 
leukemia (MLL)-rearranged AML [115, 116]. Subsequent studies in blood cancers focused on 
TET2’s role, discovering numerous mutations [117], resulting in a truncated enzyme, or one 
with compromised enzymatic activity. This was reflected in patients where a global decrease 
in 5hmC was observed in patients with homozygous or heterozygous TET2, suggesting 
that mutations in TET2 were haplo-insufficient loss-of-function mutations [118]. Aside from 
hematological malignancies, overall decreased levels of TET2, and its concomitant decrease 
in 5hmC levels have been observed in cancer of other origins such as breast, lung, liver [119], 
prostate, gastric, and melanoma [120] and glioblastomas [121].
In addition, IDH1 (isocitrate dehydrogenase 1) and IDH2, genes involved in the tricarboxylic 
acid (TCA) cycle, were found to be mutated in gliomas and AML, leading to the hypermethyl-
ation of the genome. This is attributed to the production of a metabolite which inhibits histone 
and DNA demethylation [121, 122].
3.3. Chromosomal translocations
Cancer genomes are notorious for being unstable- that is, prone to mutations in the nucleic 
acid sequences, chromosomal rearrangements, inversions, translocations and deletions. The 
consequence of this is widespread and severe, resulting in aberrant expression of genes which 
are crucial in evading apoptosis, eventuating in tumor growth.
Chromosomal translocations are an important aspect of genomic instability, where a section of 
the genome is inserted into an alternate location. This can be large sections of the genome span-
ning millions of base pairs, as in the formation of the Philadelphia chromosome through the swap 
of sections of chromosome 9 and 22 (first described in 1960 [123]), or through a small transloca-
tion (<1 kb), as is with MLL fusion genes. Interestingly, the largest proportion of chromosomal 
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translocation targets are transcription factors, wherein the fusion gene produced is still active, but 
in an aberrant manner [124]. These chromosome abnormalities are most often observed in hema-
topoietic and lymphoid tumors [125], with fusion genes involving MLL gene accounting for up to 
5–10% of ALL/AML cases, resulting in unfavorable prognoses [126].
There are two variations of MLL’s resultant fusion genes, with the chromosomal insertion 
resulting in the retention of the N or C terminus of the MLL located at 11q23, both of which 
have been identified to have oncogenic potential. The function of normal MLL is that of a 
histone methyltransferase, with its N terminus containing a CxxC domain, allowing it to 
recognize unmethylated CpG dinucleotides and its corresponding target genes [127]. The C 
terminus of MLL, on the other hand, contains features responsible for its histone methyl-
transferase activity such as a SET domain, responsible for methylation of lysine 4 of histone 
H3 [127]. The more prevalent class of fusion genes are the chimeras with the N terminus of 
MLL fused with the C terminus of the fusion partner, MLL-r (MLL-rearranged), that are also 
known to have more oncogenic potential. It has been observed that most MLL-r function to 
augment its canonical downstream targets such as the HOX cluster of genes rather than gain a 
new profile of target genes. However, the exact function of the fusion genes is entirely depen-
dent on the fusion partner. The two most common fusion gene partners of MLL are AF9 and 
AF4, which are present in the super elongation complex (SEC), and confer the fusion prod-
uct’s function of a transcription activator [128, 129]. In the chimeric gene, the fusion partner 
of MLL acts as an adaptor to the MLL portion of the gene (with DNA binding abilities) to the 
rest of the SEC, therefore resulting in aberrant expression of the downstream genes.
In a recent study, it was shown that MLL-AF9 and MLL-AF4 also bound to distal regulatory 
elements such as enhancers, and are able to deregulate its target gene expression, through inter-
play with RUNX1 [130]. Further, enhancer regions enriched for MLL-AF9 were found to be 
CTCF-rich, suggesting a novel role of MLL-AF9 in mediating 3D chromatin conformation [130].
Although most studies on fusion genes have been published in blood malignancies, recent 
studies have turned their attention to solid tumors. Fusion genes have also been found to be 
prevalent in non-blood cancers, with a similar trend of fusion partners being transcription 
factors, resulting in rampant aberrant gene expression changes (reviewed in [131]).
Another example of a fusion protein is BRD4-NUT, prominent in NUT midline carcinoma 
(NMC). The N terminus of BRD4 is conjugated with the C terminus of NUT, with retention of 
both bromodomains (from BRD4) and the KAT catalytic domain (from NUT) in the resultant 
fusion protein. This fusion protein has oncogenic potential through the formation of large 
active chromatin (1 Mb) where BRD4-NUT and histone hyperacetylation are co-localized 
[132]. In spite of the large size of chromatin which is activated, there is surprisingly only a 
small subset of genes which are upregulated, including MYC and TP63 [132].
4. Therapies targeting epigenetic factors
When considering the different ways in which biological processes are dysregulated in  cancer, 
aberrant activity of epigenetic regulators is considered one of the easiest to treat. This is mainly 
due to the fact that epigenetic dysregulation typically only occurs in specific cell types, and the 
Gene Expression and Regulation in Mammalian Cells - Transcription Toward the Establishment of Novel Therapeutics104
aberrancies are not present in all somatic cells. As such, therapies can be targeted to affected 
cancer cells, instead of requiring gene therapy to correct all somatic cells. Furthermore, epigen-
etic factors are often enzymes whose activity can be targeted, and inhibited. Therefore, diseases 
linked to epigenetic dysregulation often have a more positive prognosis with better treatment 
possibilities. Most of the epigenetic therapies currently being used are inhibitors, preventing 
the enzyme from performing its canonical function, as summarized in Table 1 and Figure 2.
The development of 5-azacytidine has been one of the most promising epigenetic therapies thus 
far, the treatment of which was seen to increase survival rate when compared to conventional care 
in MDS and AML patients [133]. 5-azacytidine is a cytosine analogue and incorporates into DNA 
and RNA, binding irreversibly to all three DNMTs, sequestering the enzymes and preventing it 
from performing its canonical functions. At low doses, treatment with DNMTi results in global 
hypomethylation (observed in LINE and Alu repetitive elements as surrogate markers of global 
hypomethylation) [134] while it is cytotoxic at higher doses [135]. 5-azacytidine also cannot be 
methylated by DNMTs, therefore curbing the phenomenon of CpG hypermethylation seen in 
cancer cells. However, different tumor types have yielded varied response rates to DNMTi, with 
solid tumors demonstrating limited sensitivity in comparison to myeloid malignancies [136]. 
This could be explained in part because DNMTi function during the S-phase of cell cycle, and 
are therefore less efficacious in solid tumors [137]. In tumors where DNMTi was found to be 
effective, aberrantly silenced tumor suppressor genes were reactivated upon treatment [138], 
contributing to the mechanism in which DNMTi can lessen tumor burden. Additionally, treat-
ment with DNMTi was found to increase the presentation of tumor antigens (such as cancer 
testis antigens (CTA)) and interferon signaling, increasing the visibility and therefore recognition 
and destruction of the tumor cells by the host [139, 140]. Endogenous retroviral elements (ERVs) 
were also observed to be increased upon treatment with DNMTi, which lead to the increase in 
cytoplasmic double-stranded RNA, inducing viral mimicry, and eventually leading to apoptosis 
[141, 142]. In contrast, treatment of IDH inhibitors have been met with limited success, with only 
a small subset of IDH-mutant cell lines demonstrating sensitivity to treatment [143]. Currently, 
there are no known TET inhibitors which prevents the demethylation of CpG islands.
Similarly, aberrant histone modifications are observed in cancer cells, and therefore drugs have 
been developed to block the activity of the enzymes that are responsible for the maintenance of 
these modifications. The majority of HDAC inhibitors that have been developed can be termed 
broad reprogrammers, which target entire classes of deacetylases instead of specific enzymes. Class 
I, II and IV of HDAC enzymes all share a similarity- that they require zinc ion to perform its 
enzymatic function, whilst class III of HDACs require NAD+ as its cofactor. As a result, it is 
easier to target these HDACs as two separate entities. There are now four inhibitors which have 
been approved by the FDA- vorinostat/SAHA (suberoylanilide hydroxamic acid), romidepsin, 
belinostat, panobinostat. However, research focus has now turned to targeting the readers of 
these acetylated marks- proteins which contain bromodomains. After reading the acetylated his-
tone marks, bromodomain-containing proteins can act as a scaffold to recruit other activating or 
repressive machinery to act on the acetylated histone tails,  regulating downstream gene expres-
sion. Inhibitors of the bromodomains of bromdomain and extra-terminal motif proteins (iBETs) 
have gained exceptional interest as of late. One of the most prominent drugs targeting bromo-
domain-containing proteins that have been developed is JQ1, named after its founding chemist, 
Jun Qi [144, 145], initially found in NUT midline carcinoma. JQ1 acts as a competitive inhibitor 
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of BRD2, BRD3, BRD4 and BRDT by reversibly binding to the hydrophobic bromodomain pock-
ets, therefore not allowing it to bind to and recognize acetylated histone tails. Since MYC is a 
known target of BRD4, the bulk of the tumorigenic effect can be attributed to the decrease in 
Targeted mechanism Canonical function Tumor type Therapeutic compound
DNA methylation







Inhibitors: 5- Azacytidine/Vidaza 
(FDA and EMA approved), decitabine 
(EMA and FDA approved) (reviewed 
in [169])
Epigenetic erasers




leukemia, AML, small 
cell lung cancer
TCP, GSK2879552 [155]
JARID1 Di and tri-methylated 
H3K4 demethylase
Lung cancer Compound 6j, prodrug 7j
Classes I, II and IV histone 
deacetylases







hydroxamic acid (SAHA) (FDA 
approved) [170], panobinostat (FDA 
approved), belinostat (FDA approved) 
Reviewed in [171, 172]
Class I histone 
deacetylases





Inhibitor: Romidepsin (FDA 




Acetylates histone tails Neuroblastoma Inhibitor: PU139, PU141 [174]
EZH2 Methylation of H3K27, 







Inhibitor: EPZ-005687 [158], GSK-126 




DOT1L Methylation of H3K79, 
and activation of genes 
involved in DNA 









Inhibitor: EPZ-5676 [165], EPZ004777 
[163, 164], SYC-522GSK2816126, CPI-
1205, [166]
G9a Methylation of H3K9 Non-small cell lung 
cancer






Solid tumors, AML, 
MDS
iBET compounds: I-BET762, I-BET151, 
RVX-208, RVX-2135 Reviewed in 
[138, 176]
Table 1. Summary of selected therapeutics targeting dysregulated gene expression regulators in cancer.
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the oncogene expression. However, the effects of iBET compounds have been shown to be not 
entirely dependent on MYC [146]. Across different tumor types, JQ1 has been shown to suppress 
tumor growth in a myriad of different ways. In glioblastoma, JQ1 has been shown to induce G1 
cell-cycle arrest and apoptosis through regulating expression of key genes such as MYC, hTERT 
and p21 [147]. Similarly in medulloblastoma, JQ1 was shown to affect cell cycle genes via activat-
ing cyclin-dependent kinase inhibitors (CDKi), reducing E2F activity and affecting p53 signaling 
[148]. However, JQ1 is not able to selectively target either of the two bromodomains on the BET 
proteins, nor between the four BRD proteins, limiting the function of JQ1 [145]. Although BRD4 
Figure 2. Graphical representation of the therapeutics against epigenetic modifiers. (A) Inhibitors of DNA 
methyltransferases, (B) histone methylases and demethylases, (C) histone acetyltransferases and deacetylases.
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is known to regulate the transcription of many cellular genes, the treatment of JQ1 only represses 
a subset of these genes. This raises the question of whether BRD4 regulates transcription in a 
manner independent from reading acetylated histone tails. This mechanism of action was later 
elucidated, where BRD4 was found to be located at super-enhancers, therefore regulating tran-
scription in a distinct manner [149]. The abovementioned iBET compounds function to only com-
petitively inhibit the function of the bromodomain-containing enzymes. Thus, recent research 
has attempted to degrade the iBET substrates by conjugating iBET to E3 ubiquitin ligases in a 
method known as proteolysis targeting chimera (PROTAC) [150, 151]. iBET compounds have 
also shown promise in NMC (where BRD4-NUT fusion protein is formed), wherein the treat-
ment with JQ1 significantly reduced tumor formation in vivo with limited cytotoxic effects [145].
Histone demethylases are another class of epigenetic erasers which can be targeted in clinic, 
of which inhibitors against LSD1 has seen the most progress. LSD1 is a member of the lysine 
demethylase (KDM) 1 family, with the ability to remove mono and di-methylated H3K4, 
therefore leading to transcriptional repression [152]. Its overexpression is linked to more 
aggressive breast and esophageal cancers, while its downregulation limits cell proliferation 
[153]. Combinatorial therapies involving the LSD1 inhibitor tranylcypromine (TCP) and 
all-trans-retinoic acid have been found efficacious in AML mouse models, and function by 
accumulating H3K4 methylation and therefore the activation of previously silenced tumor 
suppressor genes [154]. Other drugs such as GSK2879552, a derivative of TCP, has been 
developed and are currently in clinical trials for acute small cell lung cancer and AML [155]. 
Similarly, JARID1 is the demethylase of tri and di-methylated H3K4, and is observed to be 
aberrantly expressed in several cancers. Compound 6j and prodrug 7j are inhibitors which 
have been developed to inhibit JARID1 activity, with suppression of growth seen in a lung 
cancer cell line [156].
Targeted therapies are another group of drugs which have higher specificity and target spe-
cific epigenetic modifiers. EZH2 is one such target, where it has been found to be overex-
pressed in multiple cancers. The first drug to target EZH2 was 3-deazaneplanocin-A (DZNep), 
which initiates the degradation of the PRC2 complex to restore expression of silenced genes 
[157]. However, therapeutics targeting EZH2 has since evolved to target its enzymatic activ-
ity instead. EPZ-005687 is a competitive inhibitor which has high specificity for EZH2, and 
induces apoptosis via the reduction of H3K27 methylation levels in lymphoma cells [158]. 
Similar effects were observed with EPZ-6438/Tazemostat treatment, with decreased H3K27 
methylation and decreased tumor size in non-Hodgkin lymphoma mouse models [159]. 
Several small molecule inhibitors such as GSK126 [160] and UNC1999 [161] have been iden-
tified to function as EZH2 inhibitors. In mice xenografts with gain-of-function EZH2 muta-
tions, GSK126 has been shown to be effective in decreasing global levels of H3K27me3 and 
reactivating genes silenced by the PRC2 complex [160].
DOT1L is the only known histone methyltransferase of H3K79, which is often misregulated in 
AML as a result of gene translocations, leading to aberrant expression of hematopoietic stem-
cell renewal genes [162]. EPZ004777 has been shown to reduce H3K79 methylation and its sub-
sequent downregulation of downstream genes, prolonging the survival of MLL mice model 
[163, 164]. EPZ-5676 [165] and SYC-522 [166] are two drugs which are currently in clinical trials, 
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both of which have been demonstrated to efficiently decrease H3K79 methylation. G9a is the 
able to methylate H3K9, and has had inhibitors developed against it. UNC0638 is one such 
small molecule inhibitor, which results in genetic changes which phenocopy a transient deple-
tion of G9a. Expectedly, there was a concomitant global decrease in H3K9 which was observed 
[167]. However, soon after, UNC0642 was developed with improved pharmacokinetic proper-
ties [168].
As an alternative to directly targeting epigenetic modifiers, research is now expanding into 
targeting the upstream regulators of these factors such that the activity or expression of the 
histone modifiers are regulated, affecting the downstream histone modifications.
5. Conclusion
As discussed in this chapter, the regulation of gene expression is a highly complex and multi-
tiered process, regulated by a multitude of factors, summarized in Figure 3. Cancer cells have 
Figure 3. Graphical summary of gene expression regulators. Regulation of gene expression occurs at every step of the 
process, broadly divided into chromatin conformation, DNA, histone modifications, RNA and protein. Condensation 
of chromatin prevents the access of transcriptional machinery, thus repressing transcription. The mediator complex 
facilitates chromosomal looping, bringing together distal regulatory regions (and RNA Pol II) in 3D space. Histones 
undergo post-translational modification which comprise the histone code, recruiting different readers, resulting 
in different expression signatures. The proximal promoter region which contains transcription factor binding sites 
can undergo mutations and therefore inhibit canonical transcription factors from binding, or have its CpG island 
hypermethylated, therefore sterically inhibiting transcription factor binding. RNA is subject to post-transcriptional 
regulation by methylation (m6A) or via degradation by miRNA. Finally, the activity of proteins can be regulated by 
covalent modifications such as activation by acetylation/phosphorylation or by a shortened half-life by degradation.
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evolved over time to exploit these mechanisms to dysregulate many cellular processes to evade 
cell cycle checkpoints and apoptosis, to allow continued proliferation. In particular, oncogenic 
viruses have also been shown to target some of these processes to dysregulate  normal cell func-
tion, as in the case of BRD4 and TIP60, both targeted by HPV oncogenes. It can be assumed that 
oncogenic viruses would have evolved to maximize its carcinogenic potential, and therefore 
have minimal redundant functions. Therefore, the mere fact that these cellular components are 
targeted by oncogenic viruses eludes to its high canonical importance in the normal cell.
We have presented epigenetic regulating gene expression, one of the main methods in which 
either the profile of genes expression is changed, or the existing profile of genes are dysregu-
lated, leading to aberrant upregulation or downregulation. In cancer cells, the dysregulated 
pathways have to overpower the canonical functions, to tip the balance so that processes occur 
in their favor, for sustained growth. It is therefore crucial to understand the mechanisms which 
are dysregulated in cancer cells so that further therapies can be developed to target these 
aberrancies.
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Abbreviation
5-hmC 5-hydroxylmethylcytosine
ALL Acute Lymphoblastic Leukemia
AML Acute Myeloid Leukemia
ATM Ataxia-Telangiectasia Mutated
BET Bromodomain and Extra-Terminal
CDH1 Cadherin 1
CDKi Cyclin-Dependent Kinase Inhibitor
CTA Cancer Testis Antigens
CTCF CCCTC-binding Factor
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EpCAM Epithelial Cell Adhesion Molecule
ERV Endogenous Retroviral Element




iBET Inhibitors targeting Bromodomain and Extra-Terminal Motif Protein
ING Inhibitor of Growth










MYST Moz, Ybf2p/Sas3p, Sas2p and TIP60
NDR Nucleosome depleted region
NMC NUT midline carcinoma
NSCLC Non-small cell lung cancer
PHD Plant homeodomain
PRC2 Polycomb repressive complex 2
PROTAC Proteolysis targeting chimera
SAGA Spt-Ada-GCN5-Aceyl transferase
SAHA Suberoylanilide hydroxamic acid
SEC Super elongation complex
Snai1 Snail family transcriptional repressor 1
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